德国多中心成人急性淋巴细胞白血病（ALL）治疗方案（GMALL）的高效性——一项单机构研究
High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study.
作者信息
Scherrer R, Bettelheim P, Geissler K, Jäger U, Knöbl P, Kyrle P A, Laczika K, Mitterbauer G, Neumann E, Schneider B
机构信息
First Medical Department, University of Vienna, Austria.
出版信息
Ann Hematol. 1994 Oct;69(4):181-8. doi: 10.1007/BF02215951.
Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (> 35 years, p = 0.01), bcr-abl positivity (p = 0.007), and time to CR (> 4 weeks, p = 0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p = 0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration.
61例连续的急性淋巴细胞白血病（ALL）患者（排除B-ALL）接受了由霍尔泽等人[15]描述的方案治疗。完全缓解（CR）率为85%（52/61例患者）。3例患者在诱导治疗期间死亡；6例患者治疗无效。持续完全缓解（CCR）、无病生存（DFS）和总生存的中位持续时间分别为41.5、41.4和40.8个月。5年时CCR的概率为49%，DFS为43.5%，总生存为41.6%。单因素分析中，年龄较大（>35岁，p = 0.01）、bcr-abl阳性（p = 0.007）以及达到CR的时间（>4周，p = 0.05）是显著不利的预后因素。多因素分析中，只有年龄（p = 0.006）和达到CR的时间（p = 0.02）仍然具有显著性。因此，我们的数据证实了该治疗方案在CR率和缓解持续时间方面的高疗效。
Zotero 插件